<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248104</url>
  </required_header>
  <id_info>
    <org_study_id>5100064</org_study_id>
    <nct_id>NCT01248104</nct_id>
  </id_info>
  <brief_title>Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery</brief_title>
  <official_title>Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that tranexamic acid administration will be associated with 25% improvement in
      the volume of blood loss and red blood cell (RBC) administration, with no increase or a
      decrease in perioperative complications
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the Tranexamic Acid Study is the amount of blood loss per patient in the study.</measure>
    <time_frame>48 hours</time_frame>
    <description>We will be observing the amount of blood that is lost per patient in the accumulation of the chest tubes and bulb suction device outputs.
Also the total amount of blood given (in ml) to the patients in the form of blood and blood product transfusions (pRBC, platelets, fresh frozen plasma and cryoprecipitate)will be recorded.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aminocaproic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Infusion during cardiac surgery</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminocaproic Acid</intervention_name>
    <description>Infusion during cardiac surgery</description>
    <arm_group_label>Aminocaproic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is the subject 18 years of age or older?

          2. Is the subject scheduled for primary cardiac surgery utilizing cardiopulmonary
             bypass(CPB)?

          3. Is the subject more than 30 kg ( 66 lbs)?

          4. Does subject understand English?

        Exclusion Criteria:

          1. Does the subject have existing coagulation defects (INR &gt; 1.5, platelets &lt; 100 ?

          2. Does the subject have renal failure (defined as BUN/Cr ratio 20:1 ?

          3. Does the subject have severe liver disease (AST &amp; ALT&gt; 3x normal) ?

          4. Is the subject having emergency cardiac surgery, complex aortic surgery, combination
             valve/CABG surgeries, or redo cardiac surgery?

          5. Is the subject having any procedure where CPB is not anticipated?

          6. Is the patient weight greater than 150 kg?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Gatling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Jason Gatling, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Antifibrinolytic agents</keyword>
  <keyword>Blood transfusion</keyword>
  <keyword>epsilon aminocaproic acid</keyword>
  <keyword>tranexamic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Aminocaproic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 11, 2016</submitted>
    <returned>December 2, 2016</returned>
    <submitted>August 22, 2017</submitted>
    <returned>September 21, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

